2025-02-01 2026-01-31 2026-01-31 false 14622760 The Women’s Hormone Clinic Limited 86220Specialists medical practice activities iso4217:GBP xbrli:pure 146227602025-02-01 146227602026-01-31 146227602025-02-01 2026-01-31 14622760bus:SmallEntities2025-02-01 2026-01-31 14622760bus:AuditExempt-NoAccountantsReport2025-02-01 2026-01-31 14622760bus:FullAccounts2025-02-01 2026-01-31 14622760core:WithinOneYear2026-01-31 14622760core:AfterOneYear2026-01-31 14622760core:WithinOneYear2025-02-01 2026-01-31 14622760core:AfterOneYear2025-02-01 2026-01-31 14622760core:CurrentFinancialInstruments2026-01-31 14622760core:Non-currentFinancialInstruments2026-01-31 14622760core:CurrentFinancialInstruments2025-02-01 2026-01-31 14622760core:Non-currentFinancialInstruments2025-02-01 2026-01-31 14622760core:LandBuildings2025-02-01 2026-01-31 14622760core:FurnitureFittings2025-02-01 2026-01-31 14622760core:OfficeEquipment2025-02-01 2026-01-31 14622760core:Vehicles2025-02-01 2026-01-31 14622760core:PlantMachinery2025-02-01 2026-01-31 14622760core:OtherPropertyPlantEquipment2025-02-01 2026-01-31 14622760core:LandBuildings2026-01-31 14622760core:PlantMachinery2026-01-31 14622760core:Vehicles2026-01-31 14622760core:FurnitureFittings2026-01-31 14622760core:OfficeEquipment2026-01-31 14622760core:OtherPropertyPlantEquipment2026-01-31 14622760core:Right-of-useAssets2025-02-01 2026-01-31 14622760core:Right-of-useAssets2026-01-31 14622760core:Goodwill2025-02-01 2026-01-31 14622760core:PatentsTrademarksLicencesConcessionsSimilar2025-02-01 2026-01-31 14622760core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-02-01 2026-01-31 14622760core:OtherResidualIntangibleAssets2025-02-01 2026-01-31 14622760core:Goodwill2026-01-31 14622760core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-01-31 14622760core:PatentsTrademarksLicencesConcessionsSimilar2026-01-31 14622760core:OtherResidualIntangibleAssets2026-01-31 14622760dpl:CostSales2025-02-01 2026-01-31 14622760dpl:AdministrativeExpenses2025-02-01 2026-01-31 14622760dpl:DistributionCosts2025-02-01 2026-01-3114622760core:ShareCapital2026-01-31 14622760core:SharePremium2026-01-31 14622760core:RevaluationReserve2026-01-31 14622760core:OtherReservesSubtotal2026-01-31 14622760core:ShareCapitalPreferenceShares2026-01-31 14622760core:CapitalRedemptionReserve2026-01-31 14622760core:OtherCapitalReserve2026-01-31 14622760core:RetainedEarningsAccumulatedLosses2026-01-3114622760core:ShareCapital2025-02-01 2026-01-31 14622760core:SharePremium2025-02-01 2026-01-31 14622760core:RevaluationReserve2025-02-01 2026-01-31 14622760core:OtherReservesSubtotal2025-02-01 2026-01-31 14622760core:RetainedEarningsAccumulatedLosses2025-02-01 2026-01-311462276012025-02-01 2026-01-31 1462276022025-02-01 2026-01-3114622760core:ShareCapital12025-02-01 2026-01-31 14622760core:ShareCapital22025-02-01 2026-01-3114622760core:SharePremium12025-02-01 2026-01-31 14622760core:SharePremium22025-02-01 2026-01-3114622760core:RevaluationReserve12025-02-01 2026-01-31 14622760core:RevaluationReserve22025-02-01 2026-01-3114622760core:RetainedEarningsAccumulatedLosses12025-02-01 2026-01-31 14622760core:RetainedEarningsAccumulatedLosses22025-02-01 2026-01-311462276012025-02-01 2026-01-3114622760core:Non-currentFinancialInstrumentscore:CostValuation2025-02-01 14622760core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-01-3114622760core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:CostValuation2026-01-3114622760core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-02-01 14622760core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-01-31 14622760core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-01-31 14622760core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-01-3114622760core:Non-currentFinancialInstruments2026-01-31 14622760core:Non-currentFinancialInstruments2025-01-31146227602024-02-01 146227602025-01-31 146227602024-02-01 2025-01-31 14622760core:WithinOneYear2025-01-31 14622760core:AfterOneYear2025-01-31 14622760core:CurrentFinancialInstruments2025-01-31 14622760core:Non-currentFinancialInstruments2025-01-31 14622760core:LandBuildings2025-01-31 14622760core:PlantMachinery2025-01-31 14622760core:Vehicles2025-01-31 14622760core:FurnitureFittings2025-01-31 14622760core:OfficeEquipment2025-01-31 14622760core:OtherPropertyPlantEquipment2025-01-31 14622760core:Right-of-useAssets2025-01-31 14622760core:Goodwill2025-01-31 14622760core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-01-31 14622760core:PatentsTrademarksLicencesConcessionsSimilar2025-01-31 14622760core:OtherResidualIntangibleAssets2025-01-31 14622760dpl:AdministrativeExpenses2024-02-01 2025-01-3114622760core:ShareCapital2025-01-31 14622760core:SharePremium2025-01-31 14622760core:RevaluationReserve2025-01-31 14622760core:OtherReservesSubtotal2025-01-31 14622760core:ShareCapitalPreferenceShares2025-01-31 14622760core:CapitalRedemptionReserve2025-01-31 14622760core:OtherCapitalReserve2025-01-31 14622760core:RetainedEarningsAccumulatedLosses2025-01-3114622760core:RetainedEarningsAccumulatedLosses2024-02-01 14622760core:ShareCapital2024-02-01 14622760core:SharePremium2024-02-01 14622760core:RevaluationReserve2024-02-01 14622760core:ShareCapital2024-02-01 2025-01-31 14622760core:SharePremium2024-02-01 2025-01-31 14622760core:RevaluationReserve2024-02-01 2025-01-31 14622760core:OtherReservesSubtotal2024-02-01 2025-01-31 14622760core:RetainedEarningsAccumulatedLosses2024-02-01 2025-01-311462276012024-02-01 2025-01-31 1462276022024-02-01 2025-01-3114622760core:ShareCapital12024-02-01 2025-01-31 14622760core:ShareCapital22024-02-01 2025-01-3114622760core:SharePremium12024-02-01 2025-01-31 14622760core:SharePremium22024-02-01 2025-01-3114622760core:RevaluationReserve12024-02-01 2025-01-31 14622760core:RevaluationReserve22024-02-01 2025-01-3114622760core:RetainedEarningsAccumulatedLosses12024-02-01 2025-01-31 14622760core:RetainedEarningsAccumulatedLosses22024-02-01 2025-01-3114622760bus:Director12025-02-01 2026-01-3114622760bus:Director22025-02-01 2026-01-3114622760bus:Director32025-02-01 2026-01-3114622760bus:PrivateLimitedCompanyLtd2025-02-01 2026-01-31
The Women’s Hormone Clinic Limited
Unaudited Financial Statements
for the year ended 31 January 2026
Company registration number 14622760
(England and Wales)

Company Information

For the year ended 31 January 2026
Directors Ramdin, Rachel
Bernard, Andrew
Ponsford, Virginia

Registered office Crown House
27 Old Gloucester Street
London
WC1N 3AX

Registered number 14622760

Accountant Atkinsons Chartered Accountants
Palmeira Avenue Mansions
19 Church Road
Hove
England
BN3 2FA

Statement of Financial Position

As at 31 January 2026
Notes
2026
2025
£
£
£
£
Fixed assets
Intangible assets
4
2,320
-
Tangible assets
5
721
841
3,041
841
Current assets
Debtors
6
3,683
29,619
Cash at bank and in hand
27,078
757
30,761
30,376
Creditors
Amounts falling due within one year
7
(13,734)
(9,040)
(13,734)
(9,040)
Net current assets (liabilities)
17,027
21,336
Total assets less current liabilities
20,068
22,177
Net assets (liabilities)
20,068
22,177
Capital and reserves
Called up share capital
100
100
Profit and loss account
19,968
22,077
Total equity
20,068
22,177

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 21 October 2026 and are signed on its behalf by:

Bernard, Andrew
Bernard, Andrew
Director
Ponsford, Virginia
Ponsford, Virginia
Director

Company registration number 14622760

Notes to the Financial Statements

For the year ended 31 January 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.


2.3. Current taxation

Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income.


Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.

2.4. Intangible assets and amortisation

Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.

2.5. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Office and computer equipment
33
Straight-line

2.6. Trade and other debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.7. Trade and other creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.8. Related parties

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

3. Employees

The average number of employees during the year was 1 (2025: 1).

4. Intangible assets

Other intangibles
Total
£
£
Cost
Additions
2,900
2,900
At 31 January 2026
2,900
2,900
Amortisation and impairment
Other charges
580
580
At 31 January 2026
580
580
Net book value
At 31 January 2026
2,320
2,320
At 31 January 2025
-
-

5. Tangible fixed assets

Office equipment
Total
£
£
Cost
At 1 February 2025
975
975
Additions
137
137
At 31 January 2026
1,112
1,112
Depreciation and impairment
At 1 February 2025
134
134
Charge for the period
257
257
At 31 January 2026
391
391
Net book value
At 31 January 2026
721
721
At 31 January 2025
841
841

6. Debtors

2026
2025
£
£
Trade debtors
3,683
3,055
Other debtors
-
26,564
Total due within one year
3,683
29,619
Total due after one year
-
-
Total
3,683
29,619

7. Creditors due within one year

2026
2025
£
£
Trade creditors
9,013
-
Directors loan account
1,421
1,303
Taxation and social security
2,100
5,977
Accruals and deferred income
1,200
1,760
Total
13,734
9,040